MedTrace Logo

Probiotic BL NCC 2705 and Gluten Sensitivity

NCT03775499 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2020-12-23

No results posted yet for this study

Summary

The aim of the study is to confirm/prove safety of the probiotic and production of serpin in humans.

Conditions

Interventions

DIETARY_SUPPLEMENT

Intervention 1 : BL NCC 2705 + Maltodextrin

2 capsules of BL NCC 2705/day (1 in the morning and 1 in the evening) for 3 days + 1 capsule of BL NCC 2705 in the morning of the 4th day

OTHER

Intervention 1 : Maltodextrin

2 capsules of Placebo/day (1 in the morning and 1 in the evening) for 3 days + 1 capsule of Placebo in the morning of the 4th day

DIETARY_SUPPLEMENT

Intervention 2 : BL NCC 2705 + Maltodextrin

2 capsules of BL NCC 2705/day (1 in the morning and 1 in the evening) for 3 days + 1 capsule of BL NCC 2705 in the morning of the 4th day

OTHER

Intervention 2 : Maltodextrin

2 capsules of Placebo/day (1 in the morning and 1 in the evening) for 3 days + 1 capsule of Placebo in the morning of the 4th day

Sponsors & Collaborators

  • Société des Produits Nestlé (SPN)

    lead INDUSTRY

Principal Investigators

  • Carmine D'Urzo, Dr. · Nestec Ltd.

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-09
Primary Completion
2019-10-04
Completion
2020-12-15

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03775499 on ClinicalTrials.gov